GENGOS ANDREW (Chief Financial Officer) purchased 15K shares of TERNS PHARMACEUTICALS, INC. on the open market
Open‑market purchase worth $57.1K. The strongest form of insider conviction signal.
P · 3 purchases
Filed: 6/16/2025ACC: 0001562180-25-004866
Officer· Chief Financial Officer
Since Feb 2025
+15K
Net shares
Net buyer
$57.1K
Total acquired
3
Open market trades
3B · 0S
3
Total transactions
15K acquired
Non-Derivative Transactions3
Common Stock
Direct
Shares
+5K
Price / share
$3.75
Trade value
$18.75K
% of position
New position
6/13/2025
0.00→5K
Common Stock
Direct
Shares
+5K
Price / share
$3.72
Trade value
$18.60K
% of position
100.0%
6/13/2025
5K→10K
Common Stock
Direct
Shares
+5K
Price / share
$3.95
Trade value
$19.73K
% of position
50.0%
6/16/2025
10K→15K
Total
Net shares
+15K
Net value
$57.08K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/13/2025 | P · Purchase | +5K | $3.75 | $18.75K | New position | 0.00 | 5K |
| Common Stock Direct | 6/13/2025 | P · Purchase | +5K | $3.72 | $18.60K | 100.0% | 5K | 10K |
| Common Stock Direct | 6/16/2025 | P · Purchase | +5K | $3.95 | $19.73K | 50.0% | 10K | 15K |
| Total | +15K | $57.08K | ||||||
Derivative Transactions0
No derivative transactions reported